Research Analysts Offer Predictions for ALLO Q3 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for Allogene Therapeutics in a report released on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will earn ($0.36) per share for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.38) per share. Zacks Research also issued estimates for Allogene Therapeutics' FY2024 earnings at ($1.44) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.69) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%.

A number of other brokerages have also recently issued reports on ALLO. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Oppenheimer assumed coverage on Allogene Therapeutics in a report on Thursday, August 8th. They issued an "outperform" rating and a $11.00 price objective on the stock. Citigroup boosted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Truist Financial restated a "buy" rating and set a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Finally, Canaccord Genuity Group lowered their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.96.

Allogene Therapeutics Price Performance

NASDAQ ALLO traded down $0.23 on Thursday, reaching $2.54. 2,052,384 shares of the company's stock traded hands, compared to its average volume of 2,449,215. The stock has a market cap of $530.86 million, a PE ratio of -1.42 and a beta of 0.83. Allogene Therapeutics has a 12 month low of $2.01 and a 12 month high of $5.78. The stock has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $2.73.

Institutional Trading of Allogene Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its position in shares of Allogene Therapeutics by 429.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company's stock worth $25,000 after purchasing an additional 8,734 shares during the period. Private Advisor Group LLC purchased a new stake in Allogene Therapeutics in the third quarter worth about $34,000. Federated Hermes Inc. purchased a new stake in Allogene Therapeutics in the second quarter worth about $29,000. Phoenix Wealth Advisors bought a new stake in Allogene Therapeutics during the 2nd quarter valued at approximately $30,000. Finally, Algert Global LLC purchased a new position in shares of Allogene Therapeutics during the 2nd quarter worth approximately $35,000. Institutional investors own 83.63% of the company's stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).